We are live on ! Find out more
BIS icon

ProShares UltraShort NASDAQ Biotechnology
BIS

8 hedge funds and large institutions have $984K invested in ProShares UltraShort NASDAQ Biotechnology in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more funds holding

Funds holding: 7 → 8 (+1)

3.5% more ownership

Funds ownership: 15.41% → 18.91% (+3.5%)

5% more capital invested

Capital invested by funds: $938K → $984K (+$46.5K)

20% less call options, than puts

Call options by funds: $8K | Put options by funds: $10K

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Holders
8
Holders Change
+1
Holders Change %
+14.29%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
4
Closed
–
Calls
$8K
Puts
$10K
Net Calls
-$2K
Net Calls Change
-$29K

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$132K
2
Simplex Trading
Simplex Trading
Illinois
+$6.51K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$50.3K
2
Citadel Advisors
Citadel Advisors
Florida
-$44.8K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$21.9K
4
Morgan Stanley
Morgan Stanley
New York
-$595

BIS Hedge Fund Activity: Q2 2023 in Review

8 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q2 2023, worth a combined $984K — up 5% from $938K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new BIS positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 4 trimmed.

The largest buyer was Tower Research Capital (TRC), adding an estimated $132K. The largest seller was UBS Group, cutting an estimated $50.3K.

  • 8 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q2 2023, up from 7 in Q1 2023.
  • Funds reported $984K of ProShares UltraShort NASDAQ Biotechnology stock for Q2 2023, up 5% quarter-over-quarter.
  • 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q2 2023 and 0 closed out, a net change of +1 holder.
  • The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q2 2023 was Tower Research Capital (TRC), an estimated $132K added.
  • The largest ProShares UltraShort NASDAQ Biotechnology seller in Q2 2023 was UBS Group, an estimated $50.3K sold.

Based on aggregated 13F filings for Q2 2023.